The REFLECT Trial - A Randomized Evaluation of the TriGuard HDH Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions after TransCatheter Aortic Valve Implantation
The REFLECT Trial
Sponsor: Keystone Heart
Enrolling: Male and Female Patients
IRB Number: AAAQ9626
U.S. Govt. ID: NCT02536196
Contact: Lauren Privitera: 212-342-3488 / lp2183@cumc.columbia.edu
Additional Study Information: This is a research study designed to look at the safety and effectiveness of the TriGUARD 3 cerebral embolic protection device in patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of the study is to assess whether the TriGUARD 3 can prevent death, stroke, more subtle signs of brain injury, and/or silent brain injury as measured by a magnetic resonance imaging (MRI) study of the brain.
This study is closed
Investigator
Susheel Kodali, MD
Do You Qualify?
Are you 18 years or older Yes No
Is your physician planning an aortic valve procedure in the future Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Lauren Privitera
lp2183@cumc.columbia.edu
212-342-3488
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE